NO20084546L - Diagnostikk og behandlinger for tumorer - Google Patents

Diagnostikk og behandlinger for tumorer

Info

Publication number
NO20084546L
NO20084546L NO20084546A NO20084546A NO20084546L NO 20084546 L NO20084546 L NO 20084546L NO 20084546 A NO20084546 A NO 20084546A NO 20084546 A NO20084546 A NO 20084546A NO 20084546 L NO20084546 L NO 20084546L
Authority
NO
Norway
Prior art keywords
diagnosis
tumors
treatments
methods
treating cancer
Prior art date
Application number
NO20084546A
Other languages
English (en)
Norwegian (no)
Inventor
Napoleone Ferrara
Hans-Peter Gerber
Megan Baldwin
Farbod Shojaei
Cuiling Zhong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20084546L publication Critical patent/NO20084546L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20084546A 2006-03-29 2008-10-28 Diagnostikk og behandlinger for tumorer NO20084546L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78772006P 2006-03-29 2006-03-29
PCT/US2007/065377 WO2007115045A2 (en) 2006-03-29 2007-03-28 Diagnostics and treatments for tumors

Publications (1)

Publication Number Publication Date
NO20084546L true NO20084546L (no) 2008-12-23

Family

ID=38564192

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084546A NO20084546L (no) 2006-03-29 2008-10-28 Diagnostikk og behandlinger for tumorer

Country Status (19)

Country Link
US (2) US20070264193A1 (enExample)
EP (1) EP1999151A2 (enExample)
JP (1) JP2009531463A (enExample)
KR (1) KR20080106946A (enExample)
CN (1) CN101448856A (enExample)
AR (1) AR060228A1 (enExample)
AU (1) AU2007233237A1 (enExample)
BR (1) BRPI0709425A2 (enExample)
CA (1) CA2647430A1 (enExample)
CL (1) CL2007000876A1 (enExample)
CR (1) CR10325A (enExample)
IL (1) IL193842A0 (enExample)
MA (1) MA30348B1 (enExample)
MX (1) MX2008012279A (enExample)
NO (1) NO20084546L (enExample)
RU (1) RU2008142775A (enExample)
TW (1) TW200806322A (enExample)
WO (1) WO2007115045A2 (enExample)
ZA (1) ZA200807590B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2006094014A2 (en) 2005-02-28 2006-09-08 The Regents Of The University Of California Methods for diagnosis and treatment of endometrial cancer
US8318906B2 (en) 2005-04-15 2012-11-27 The Regents Of The University Of California EMP2 antibodies and their therapeutic uses
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US20110118185A9 (en) * 2007-02-21 2011-05-19 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2705486C (en) * 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
WO2009075768A2 (en) * 2007-12-07 2009-06-18 Children's Hospital Of Orange County Optical device and method for real-time chemosensitivity testing
EP2649995A3 (en) * 2008-02-29 2014-05-21 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of post-radiation tumor growth
WO2010017083A1 (en) * 2008-08-04 2010-02-11 Wayne State University Methods of treating cancer with cd11b antibodies
WO2010025414A2 (en) * 2008-08-29 2010-03-04 Genentech, Inc. Diagnostics and treatments for vegf-independent tumors
US20110190380A1 (en) * 2008-10-23 2011-08-04 Elena Feinstein Methods for delivery of sirna to bone marrow cells and uses thereof
US9498431B2 (en) 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
WO2010075420A1 (en) * 2008-12-23 2010-07-01 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
US7615353B1 (en) 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
AU2010278844A1 (en) * 2009-07-31 2012-02-09 Genentech, Inc. Inhibition of tumor metastasis using Bv8- or G-CSF-antagonists
KR20120059553A (ko) * 2009-08-14 2012-06-08 제넨테크, 인크. Ｖｅｇｆ 길항제에 대한 환자 반응을 모니터링하기 위한 생물학적 마커
US7736861B1 (en) 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
JP5911805B2 (ja) 2009-11-20 2016-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 上皮膜タンパク質−２（ｅｍｐ２）および増殖性硝子体網膜症（ｐｖｒ）
CA2790500A1 (en) * 2010-02-19 2011-08-25 Lynn K. Gordon Epithelial membrane protein 2 (emp2) binding reagents and their therapeutic uses in ocular diseases
US9375473B2 (en) 2010-02-19 2016-06-28 Cornell Research Foundation, Inc. Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
KR101313184B1 (ko) * 2010-06-24 2013-09-30 한국표준과학연구원 질병 지표 검출 키트 및 질병 지표 검출 방법
RU2014109985A (ru) * 2011-08-17 2015-09-27 Дженентек, Инк. Ингибирование ангиогенеза в рефрактерных опухолях
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
RU2502471C9 (ru) * 2012-08-21 2015-04-20 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ оценки соответствия размеров селезенки норме или отклонению от нее у детей методом ультразвуковой диагностики
EP2741086A1 (en) * 2012-12-06 2014-06-11 Ludwig Boltzmann Gesellschaft Method for measuring coagulation of blood samples using viscoelastic tests (VET)
WO2014127785A1 (en) * 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014159923A1 (en) * 2013-03-13 2014-10-02 Health Research, Inc. Enhancement of vaccines
RU2546105C1 (ru) * 2014-04-29 2015-04-10 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ оценки методом ультразвуковой диагностики соответствия размеров селезенки норме или отклонению от нее у детей от 3 до 15 лет
WO2018078158A1 (en) * 2016-10-31 2018-05-03 Hexal Ag Antibody preparation
WO2020023183A1 (en) * 2018-07-24 2020-01-30 So Young Life Sciences Corporation Use of liposomes to deliver a protein and a gene encoding the protein to a live cell
US20200347449A1 (en) * 2019-05-01 2020-11-05 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
CN112946291A (zh) * 2019-12-10 2021-06-11 上海交通大学医学院附属仁济医院 Fgf18在制备诊断和预测卵巢癌试剂中的应用及fgf18化学发光检测试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840793A (en) * 1987-06-11 1989-06-20 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US20020032313A1 (en) * 1991-03-29 2002-03-14 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE4422551C1 (de) * 1994-06-28 1995-07-27 Daimler Benz Ag Durch Servomotor unterstützte Zahnstangenlenkung
US5871697A (en) * 1995-10-24 1999-02-16 Curagen Corporation Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
WO1998045331A2 (en) * 1997-04-07 1998-10-15 Genentech, Inc. Anti-vegf antibodies
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU4972900A (en) * 1999-04-08 2000-11-14 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
ATE363291T1 (de) * 2000-06-23 2007-06-15 Bayer Schering Pharma Ag Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren
WO2003068155A2 (en) * 2002-02-12 2003-08-21 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
RS20050885A (sr) * 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition

Also Published As

Publication number Publication date
MX2008012279A (es) 2008-10-08
KR20080106946A (ko) 2008-12-09
AU2007233237A1 (en) 2007-10-11
MA30348B1 (fr) 2009-04-01
JP2009531463A (ja) 2009-09-03
BRPI0709425A2 (pt) 2011-07-12
CL2007000876A1 (es) 2008-02-08
US20100239568A1 (en) 2010-09-23
ZA200807590B (en) 2009-11-25
TW200806322A (en) 2008-02-01
WO2007115045A3 (en) 2008-04-03
EP1999151A2 (en) 2008-12-10
CN101448856A (zh) 2009-06-03
WO2007115045A2 (en) 2007-10-11
US20070264193A1 (en) 2007-11-15
AR060228A1 (es) 2008-06-04
CA2647430A1 (en) 2007-10-11
RU2008142775A (ru) 2010-05-10
IL193842A0 (en) 2011-08-01
CR10325A (es) 2008-12-03

Similar Documents

Publication Publication Date Title
NO20084546L (no) Diagnostikk og behandlinger for tumorer
EA200901550A1 (ru) Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений
NO20071791L (no) Preparater og fremgangsmater for diagnostiseringen og behandlingen av tumor
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
IL258880A (en) Diarylhydantoin compounds
LTPA2017011I1 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
NO20090450L (no) Tumorterapi med at anti-VEGF antistoff
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
ECSP099523A (es) Antagonistas específicos de VEGF para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadíos tempranos
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
CY1114050T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
NO20056236L (no) Behandling med anti-VEGF-antistoffer
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
MX338754B (es) Anticuerpos humanos contra el factor tisular.
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
WO2007141280A3 (en) Proteins
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
WO2010025414A3 (en) Diagnostics and treatments for vegf-independent tumors
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
NO20084795L (no) Fremgangsmate for a behandle, diagnostisere eller detektere kreft
EP1742654A4 (en) ANTI-LFL2 ANTIBODIES FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER
EP1993672A4 (en) Na/k-atpase ligand

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application